Loading
Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma.
Philippe Armand is a lymphoma specialist at Dana-Farber Cancer Institute. He was first author of the 2019 Journal of Clinical Oncology report of KEYNOTE-170, in which pembrolizumab produced durable responses in relapsed or refractory primary mediastinal large B-cell lymphoma, supporting its approval in that setting, and was a lead investigator of the trials of nivolumab and pembrolizumab in relapsed classical Hodgkin lymphoma.
| Title | Journal | Year |
|---|---|---|
| KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma | Journal of Clinical Oncology | 2019 |
Shares Non-Hodgkin lymphoma (all types) and the tags lymphoma, trialist.
Shares Dana-Farber Brigham Cancer Center, Non-Hodgkin lymphoma (all types) and the tags lymphoma, trialist.
Shares the tags lymphoma, trialist.
Shares KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma, Primary mediastinal (thymic) large B-cell lymphoma.
Shares the tags immunotherapy, trialist.
Shares the tags immunotherapy, trialist.
Shares the tags lymphoma, trialist.
Shares the tags immunotherapy, trialist.